TEVA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
4.4B
+6.1%
4.1B
+4.0%
4.0B
-15.5%
4.7B
+5.2%
4.5B
Cost of Revenue
2.0B
-1.7%
2.0B
-1.1%
2.0B
-2.2%
2.1B
-5.5%
2.2B
Gross Profit
2.4B
+13.3%
2.2B
+9.2%
2.0B
-25.8%
2.7B
+15.2%
2.3B
Operating Expenses
1.7B
-27.6%
2.4B
+80.7%
1.3B
-44.0%
2.4B
+65.7%
1.4B
R&D
297.0M
-69.4%
970.0M
+336.9%
222.0M
-16.9%
267.0M
+4.3%
256.0M
SG&A
1.0B
-2.6%
1.0B
+3.4%
1.0B
-10.7%
1.1B
+15.1%
973.0M
Operating Income
714.0M
+409.1%
-231000000
-135.4%
652.0M
+118.1%
299.0M
-66.1%
882.0M
EBITDA
1.4B
+254.3%
409.0M
-59.0%
997.0M
-34.6%
1.5B
+15.7%
1.3B
Net Income
234.0M
+140.6%
-576000000
-255.7%
370.0M
-23.1%
481.0M
+10.8%
434.0M
EPS (Basic)
$0.20
+140.8%
$-0.49
-253.1%
$0.32
-23.8%
$0.42
+10.5%
$0.38
EPS (Diluted)
$0.20
+140.8%
$-0.49
-258.1%
$0.31
-24.4%
$0.41
+10.8%
$0.37
Shares (Diluted)
1.2B
+1.5%
1.2B
-1.2%
1.2B
+0.9%
1.2B
+0.3%
1.2B
Teva Pharmaceutical Industries (TEVA) — Financials